GLP-1 and Gallbladder Problems: Gallstone Risk, Symptoms, Data
You have likely heard it mentioned in forums or seen a cautious note in the fine print: “gallbladder problems” can occur with GLP-1 medications. The good news is, this is not some hidden or mysterious risk. It has been observed in clinical trials, quantified, and studied. The less comforting news is that it is real: in the STEP 1 semaglutide trial, gallbladder-related events occurred at about twice the placebo rate, though the gap was smaller in some other trials.
This guide walks through what the data actually shows, why gallbladder disease happens more often with GLP-1 medications, what symptoms matter, and what to do if you develop one.
Understanding the Risk: The Clinical Trial Data
The increased gallbladder disease risk with GLP-1 medications is not speculation or anecdotal reporting. It has been documented in multiple large, randomized controlled trials.
STEP 1 Trial (Semaglutide)
The STEP 1 trial was a landmark trial that evaluated semaglutide for weight management in people without diabetes. Over 1,900 adults were randomized to receive either semaglutide or placebo, with the trial lasting 68 weeks.
Gallbladder-related disorders (mostly gallstones, also called cholelithiasis) occurred in:[1]
- 2.6% of semaglutide-treated patients
- 1.2% of placebo patients
In this trial, that was roughly a two-fold difference. While 2.6% may sound small on its face, it was a real and measurable increase over the placebo rate. The FDA prescribing information for semaglutide 2.4 mg, which pools its adult weight-reduction trials, reports cholelithiasis (gallstones) in 1.6% of injection-treated adults versus 0.7% on placebo, and cholecystitis in 0.6% versus 0.2%.[8]
SURMOUNT-1 Trial (Tirzepatide)
SURMOUNT-1 evaluated tirzepatide (a dual GLP-1/GIP receptor agonist) in a similar population of 2,539 adults over 72 weeks.[2]
In the FDA prescribing information for tirzepatide for weight reduction, which pools two weight-reduction trials including SURMOUNT-1:[5]
- Cholelithiasis (gallstones): 1.1% of tirzepatide-treated patients vs 1% on placebo
- Cholecystitis: 0.7% of tirzepatide-treated patients vs 0.2% on placebo
- Cholecystectomy (gallbladder removal): 0.2% vs none on placebo
Gallstone rates were close to placebo, while gallbladder inflammation was more common in the group receiving the active medication. The label notes that acute gallbladder events were associated with weight reduction.
SELECT Trial Confirmation
The SELECT trial, published in 2023, was a large cardiovascular outcomes trial of semaglutide in 17,604 people with established cardiovascular disease and overweight or obesity, without diabetes.[3] In its published safety analysis, gallbladder-related disorders were more frequent with semaglutide than placebo (2.8% vs 2.3%), mainly driven by gallstones (1.4% vs 1.1%), while cholecystitis was similar between groups (0.6% vs 0.6%).[6]
Across 76 randomized trials, a 2022 meta-analysis found GLP-1 medications were associated with a higher risk of gallbladder or biliary disease overall (relative risk 1.37), and the increase was larger in weight-loss trials (relative risk 2.29), at higher doses, and with longer use.[7]
Why GLP-1 Medications Increase Gallbladder Disease Risk
There are two mechanisms at work.
Mechanism 1: Reduced Gallbladder Motility
GLP-1 medications slow the transit of food through your digestive system and may also slow how the gallbladder empties after a meal. The gallbladder normally contracts after eating, ejecting bile into the small intestine to help digest fat.
When the gallbladder does not contract effectively, bile sits in the gallbladder longer and becomes more concentrated. When bile becomes overly concentrated, cholesterol (a component of bile) can precipitate out of solution and form crystals, which are the precursors to gallstones.
In a small randomized trial of liraglutide, an earlier GLP-1 medication, the gallbladder took longer to reach its maximum emptying after a meal than on placebo, although the maximum amount emptied did not differ.[4] Anything that reduces how often or how forcefully the gallbladder contracts increases the risk of stone formation.
Mechanism 2: Significant Weight Loss
GLP-1 medications can lead to meaningful weight loss over time. This weight loss, independent of the medication itself, is a known risk factor for gallstone formation.
Weight loss causes the liver to mobilize fat and increase cholesterol secretion into bile. Combined with reduced gallbladder contractility, this creates an environment where gallstone formation becomes more likely.
Research into bariatric surgery (which causes substantial weight loss in a short period) shows that gallstone formation is common in the months after surgery. Rapid, substantial weight loss is itself a recognized risk factor.
With GLP-1 medications, you may experience significant weight loss AND reduced gallbladder motility at the same time. This is why the risk shows up across trials. The semaglutide label adds that gallbladder disease was more common on the medication than on placebo even after accounting for the amount of weight lost.[8]
Absolute vs. Relative Risk: Understanding the Numbers
When you read that a GLP-1 medication doubled the rate of gallbladder events in a trial, it is important to understand what that means in absolute terms.
In the STEP 1 trial, the absolute numbers were:
- 2.6 out of 100 people on semaglutide developed gallbladder-related events
- 1.2 out of 100 people on placebo developed gallbladder-related events
The difference is about 1.4 per 100, or roughly 1 in 70 people.
This matters because while the relative increase (about double in STEP 1) sounds alarming, the absolute risk is still modest. Most people who take GLP-1 medications will not develop gallstones or gallbladder disease. But it is not a negligible risk either, and it warrants awareness and monitoring.
Who Is at Higher Risk?
Certain factors increase your likelihood of developing gallstones on GLP-1 medication.
Personal or family history of gallstones: If you have had gallstones before, or if gallstones or gallbladder disease run in your family, your baseline risk is already elevated. GLP-1 medications may increase it further. Active gallbladder disease is one of the conditions a prescriber typically asks about before starting a GLP-1, and our guide to GLP-1 contraindications explains which health conditions can affect whether these medications are appropriate for you.
Female sex: Women are more likely than men to develop gallstones, even without medication. This is partly due to estrogen’s effect on bile chemistry. If you are a woman, especially in your 40s or 50s, you start with a higher baseline risk.
Pace of weight loss: The faster you lose weight, the higher your gallstone risk. GLP-1 medications may lead to greater weight loss than diet or exercise alone, which can amplify this risk.
Age: Gallstone risk increases with age.
Certain dietary patterns: Very low-fat diets and skipping meals can increase gallstone risk because the gallbladder does not get the stimulus to contract. Conversely, regular eating with adequate fat triggers normal gallbladder function.
Symptoms That Warrant Evaluation
Most gallstones are asymptomatic. You can have gallstones and never know it. The risk with GLP-1 medications is primarily for symptomatic gallstone disease or acute cholecystitis (gallbladder infection or inflammation).
Pain That Suggests Gallbladder Issues
The classic gallbladder pain is located in the right upper quadrant of the abdomen (under your right rib cage). The pain often:
- Comes on suddenly and intensifies over a few minutes
- Lasts between 30 minutes and a few hours (not constant all day)
- Occurs after eating, particularly after eating fatty foods
- May radiate to your right shoulder blade or right shoulder (referred pain, because of how nerves are distributed)
- Is sometimes accompanied by nausea or vomiting
Acute Cholecystitis
Cholecystitis is inflammation or infection of the gallbladder, often triggered by a gallstone blocking the cystic duct. Symptoms include:
- Severe right upper quadrant pain that persists (not intermittent)
- Fever (a temperature above 100.4 F or 38 C)
- Nausea or vomiting
- Right upper abdominal tenderness (hurts when the area is pressed)
- Possible jaundice (yellowing of skin or eyes), though this is less common
Fever with abdominal pain is a red flag. Cholecystitis can progress to infection or perforation of the gallbladder if not treated promptly. If you have fever and abdominal pain, seek evaluation without delay.
When to Contact Your Provider
Do not wait for a routine appointment if you experience:
- Severe, persistent pain in the right upper abdomen
- Right upper abdominal pain accompanied by fever
- Persistent nausea or vomiting with abdominal pain
- Jaundice (yellowing of skin or sclera, the whites of the eyes)
Reach out to your provider immediately. Many of these conditions require imaging (ultrasound or CT scan) to diagnose, and some require urgent treatment.
Mild, intermittent pain that resolves on its own can be mentioned at your next routine appointment, but do not assume it will go away. Keep track of when it occurs, what you ate beforehand, and how long it lasts. This information helps your provider decide whether imaging is warranted.
Treatment and Management
If you develop gallstones or are diagnosed with cholecystitis, your treatment depends on whether symptoms are present and how severe they are.
Asymptomatic Gallstones
If imaging (ultrasound) detects gallstones but you have no symptoms, the standard approach is “watchful waiting.” You do not need surgery. You do not need medication. Many gallstones found by chance never cause symptoms.
However, your provider may recommend continued monitoring, especially if you have known risk factors (family history, female sex, significant weight loss). Your provider may also discuss whether to continue or temporarily pause your GLP-1 medication while the situation stabilizes.
Symptomatic Gallstones
If you have symptomatic gallstones (recurrent pain that matches the description above), your provider will likely recommend imaging to confirm the diagnosis. If confirmed, the standard treatment is cholecystectomy (surgical removal of the gallbladder).
This is a common procedure, typically done laparoscopically (minimally invasive, using small incisions and a camera). Recovery is usually quick, and most people do well without a gallbladder. You can still eat normally, though some people experience increased stool frequency or looser stools after the surgery.
Acute Cholecystitis
Acute cholecystitis is a medical emergency. If your provider suspects it based on symptoms and imaging, you may need hospitalization, IV antibiotics, and likely surgical removal of the gallbladder. The sooner you seek treatment, the lower the risk of serious complications like perforation or sepsis.
Whether to Continue GLP-1 Medication
This is a conversation for you and your provider, not a decision to make on your own. Some patients with symptomatic gallstone disease pause their GLP-1 medication while they recover from surgery or while symptoms are being managed. Others continue the medication if their provider assesses that the benefits outweigh the risks in their specific situation.
Do not stop your medication without talking to your provider first. Abruptly stopping can lead to rebound appetite increase and rapid weight regain, and it may not actually address the underlying gallbladder issue.
Monitoring and Prevention Strategies
While there is no way to completely prevent gallstone formation if you are predisposed and taking a GLP-1 medication, a few strategies may help:
Regular Monitoring
Your provider should assess you for gallbladder symptoms at each visit. The prescribing information does not call for routine gallbladder imaging before starting. It says that if gallstones are suspected (Wegovy) or cholecystitis is suspected (Zepbound), gallbladder studies and appropriate clinical follow-up are indicated.[5][8] If you have known risk factors (family history, prior gallstones), ask your provider how they plan to monitor you.
Regular, Balanced Eating
Eating regularly and including adequate fat at meals stimulates normal gallbladder contraction, which helps prevent bile stasis (bile sitting and becoming concentrated). Skipping meals or following very low-fat diets can increase gallstone risk. Aim for balanced meals with protein, carbohydrates, and moderate fat. Because reduced appetite makes it easy to go most of the day without eating, our guide to meal timing on GLP-1 medications covers how to space meals so your gallbladder keeps getting a regular signal to contract.
Gradual Weight Loss
While the weight loss from GLP-1 medications is one of their benefits, working closely with your provider to titrate your dose and manage your eating patterns helps ensure weight loss is steady and sustainable, rather than extremely rapid. Slower weight loss is associated with lower gallstone risk than extremely rapid loss. For some patients, this conversation includes staying on a lower tirzepatide dose to reduce side effects, which may also mean a more gradual pace of weight loss.
Lab Work and Provider Communication
Some programs include regular lab work and provider check-ins; others bill labs separately or ask you to get them through your own primary care provider. If you are comparing programs, ask how often the prescriber checks in during dose increases and how to reach them between visits. Use those check-ins to report any symptoms, even mild ones. Gallbladder symptoms can be vague early on, and your provider is equipped to help you sort out whether imaging or further evaluation is needed.
The Bottom Line
GLP-1 medications, including semaglutide and tirzepatide, are associated with an increased risk of gallbladder disease. In a 2022 meta-analysis of weight-loss trials, the risk was about 2.3 times that of placebo or comparison treatments, though the size of the increase varies by medication and type of event.[1][5][7] This is a real risk, observed in clinical trials and confirmed across multiple studies. However, it is not guaranteed to happen to you.
Most people on GLP-1 medications do not develop symptomatic gallbladder disease. Of those who do, many have asymptomatic gallstones that never cause problems. And most symptomatic cases can be managed successfully with medical or surgical intervention.
What matters is awareness and monitoring. Know what symptoms to watch for. Report them to your provider. Work with your provider on regular check-ins and lab work. And understand that this is one of several side effects GLP-1 medications can cause, balanced against their weight loss and metabolic benefits for your individual situation.
Your provider will help you weigh these risks and benefits as you decide whether GLP-1 therapy is right for you. If you are still at that deciding stage, our GLP-1 eligibility guide walks through what prescribers typically look for and how online evaluations at telehealth programs usually work.
STEP 1: Semaglutide Gallbladder Events
2.6%
vs 1.2% placebo
Tirzepatide Weight-Reduction Trials: Cholecystitis
0.7%
vs 0.2% placebo (FDA label)
Relative Risk in Weight-Loss Trials
2.3x
Gallbladder or biliary disease, 2022 meta-analysis
Symptoms vs. Risk Factors: Know the Difference
Symptoms That Need Evaluation
- Pain in right upper abdomen, especially after eating fatty foods
- Pain radiating to right shoulder or shoulder blade
- Nausea or vomiting with abdominal pain
- Fever with abdominal pain (seek immediate care)
- Jaundice (yellowing of skin or eyes)
- Persistent or worsening discomfort
Risk Factors That Increase Your Odds
- Female sex (higher baseline risk than males)
- Age 40 and older
- Family history of gallstones or gallbladder disease
- Personal history of prior gallstones
- Significant weight loss (common with GLP-1s)
- Very low-fat diet or frequent meal skipping
- Estrogen exposure (oral contraceptives, HRT)
Read Next
For more on GLP-1 safety and side effects, read our complete side effects guide or our overview of GLP-1 long-term safety.
For a broader understanding of life on a GLP-1 medication, visit the GLP-1 Patient Guide.
Citations
[1] Wilding JPH, Batterham RL, Calanna S, et al. “Once-weekly semaglutide in adults with overweight or obesity.” New England Journal of Medicine. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
[2] Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
[3] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
[4] Nexoe-Larsen CC, Sorensen PH, Hausner H, et al. “Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity.” Diabetes, Obesity and Metabolism. 2018;20(11):2557-2564. https://pubmed.ncbi.nlm.nih.gov/29892986/
[5] Eli Lilly and Company. Zepbound (tirzepatide) injection, prescribing information, Section 5.4 Acute Gallbladder Disease. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
[6] Kushner RF, Ryan DH, Deanfield J, et al. “Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.” Obesity (Silver Spring). 2025;33(3):452-462. https://pubmed.ncbi.nlm.nih.gov/39948761/
[7] He L, Wang J, Ping F, et al. “Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.” JAMA Internal Medicine. 2022;182(5):513-519. https://pubmed.ncbi.nlm.nih.gov/35344001/
[8] Novo Nordisk. Wegovy (semaglutide) injection and tablets, prescribing information, Section 5.3 Acute Gallbladder Disease. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation, and never start, stop, or change a medication without guidance from your prescriber. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound; they may differ in formulation, purity, and potency. Results vary. Trial results describe study participants and are not a prediction for any individual. Wegovy is a trademark of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.